Search results for " inhalation"

showing 10 items of 231 documents

Analysis of interleukin-6 and interleukin-8 in lung transplantation: correlation with nitric oxide administration.

2008

Introduction and Objectives. Primary graft dysfunction (PGD) following lung transplantation (LT) is associated with an activation of the inflammatory cascade and release of cytokines. Inhaled nitric oxide (iNO) provides specific pulmonary vasodilatation and improves oxygenation. Our objective was to verify whether administering iNO to LT patients modified the blood and bronchoalveolar lavage (BAL) interleukin (IL)-6 and -8 levels in the event of PGD. Materials and Methods. Thirty-two LT patients were randomized to the iNO treatment or the control group. Patients in the first group were given 10 ppm of iNO from the start of LT until 48 hours afterward. BAL and peripheral arterial blood sampl…

AdultGraft Rejectionmedicine.medical_specialtyAdolescentmedicine.medical_treatmentNitric OxideGastroenterologyNitric oxidechemistry.chemical_compoundYoung AdultPostoperative ComplicationsInternal medicineAdministration InhalationmedicineLung transplantationHumansInterleukin 6AgedInflammationTransplantationLungmedicine.diagnostic_testbiologybusiness.industryInterleukin-6Interleukin-8Interleukinrespiratory systemMiddle AgedBronchodilator AgentsTransplantationBronchoalveolar lavagemedicine.anatomical_structurechemistryAnesthesiabiology.proteinArterial bloodSurgerybusinessLung TransplantationTransplantation proceedings
researchProduct

Humidity of Anaesthetic Gases with Respect to Low Flow Anaesthesia

1994

It has been demonstrated in an experimental study in swine using the scanning electron microscope that a rebreathing technique utilising minimal fresh gas flowrates significantly improves climatization of anaesthetic gases. Consequently, effects of various anaesthetic techniques on airway climate must be assessed, which covers the need for suitable measuring devices. Basic principles and methods of humidity measurement in flowing anaesthetic gases include gravimetric hygrometry, dew point hygrometry, wet-dry bulb psychrometry, mass spectrometry, spectroscopic hygrometry and electrical hygrometry. A custom-made apparatus for continuous measurement of humidity and temperature in the inspired…

AdultHot TemperatureTime FactorsSwineThermometersPartial PressureAnalytical chemistryBronchiCritical Care and Intensive Care MedicineAbsorption03 medical and health sciences0302 clinical medicineAnesthesia Closed-CircuitTidal VolumeAnimalsHumansMedicineCiliaDesiccation030223 otorhinolaryngologyMoistureHygrometerbusiness.industryElectric ConductivityWaterHumidityHumidity030208 emergency & critical care medicineEquipment DesignPartial pressureRespiration ArtificialFresh gas flowVolumetric flow rateTracheaMucusAnesthesiology and Pain MedicineDew pointAnesthesiaAnesthetics InhalationGravimetric analysisVolatilizationPulmonary VentilationbusinessAnaesthesia and Intensive Care
researchProduct

Normal and abnormal pulmonary ventilation: visualization at hyperpolarized He-3 MR imaging.

1996

To assess the feasibility of helium-3 magnetic resonance (MR) imaging with a three-dimensional fast low-angle shot (FLASH) sequence, He-3 gas (volume, 300 mL; pressure, 3 x 10(5) Pa; polarized up to 45% by means of optimal pumping) was inhaled by five healthy volunteers and five patients with pulmonary diseases. All breath-hold examinations (22-42 seconds) were completed successfully. Normal ventilation was depicted with homogeneous high signal intensity, lesions were depicted as causing defects, and obstructive lung disease was depicted with severely inhomogeneous signal intensity.

AdultLung DiseasesBronchiHyperpolarized Helium 3Respiratory physiologyHeliumIsotopesAdministration InhalationmedicineHumansRadiology Nuclear Medicine and imagingLungmedicine.diagnostic_testbusiness.industryRespirationRespiratory diseaseMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance ImagingMr imagingObstructive lung diseaseTracheaHomogeneousBreathingNuclear medicinebusinessRadiology
researchProduct

What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?

2013

<b><i>Background and Objective:</i></b> We aimed to explore to what extent an unselected population of chronic obstructive pulmonary disease (COPD) outpatients would be eligible for inclusion in randomized clinical trials (RCTs). <b><i>Methods:</i></b> Retrospective analysis of the clinical records of outpatient subjects with an ascertained diagnosis of COPD. COPD outpatients were assessed against the following inclusion criteria: 40 < age < 80 years, current or former smokers, forced expiratory volume in the first second (FEV<sub>1</sub>) <70% predicted, no long-term oxygen therapy, no other concomitant lung diseases and …

AdultLung DiseasesMalePulmonary and Respiratory Medicinemedicine.medical_specialtyMEDLINEPulmonary diseaseComorbiditySettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionCohort StudiesPulmonary Disease Chronic ObstructiveRandomized controlled triallawForced Expiratory VolumeInternal medicinePragmatic Clinical Trials as TopicmedicineHumansCOPDAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overCOPDbusiness.industryPatient SelectionSmokingAge FactorsOxygen Inhalation TherapyRetrospective cohort studyMiddle Agedmedicine.diseaseComorbidityBronchiectasisrespiratory tract diseasesPhysical therapyFemaleObservational studyCognition DisordersbusinessCohort study
researchProduct

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma

2018

Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists. Overall, 140 patients were randomised to tralokinumab 300 mg or placebo (n=70 in each group) administered subcutaneously every 2 weeks. The primary end-point was percentage change from baseline in average OCS dose at week 40, while maintaining asthma control. Secondary end-points included proportion of patients with a prescribed maintenance OCS do…

AdultMale0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classAdministration OralPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsAdverse effectAgedInhalationRespiratory tract infectionsbusiness.industryAntibodies MonoclonalMiddle AgedAsthmaClinical trialTreatment Outcome030104 developmental biology030228 respiratory systemDisease ProgressionCorticosteroidFemalebusinessTralokinumabEuropean Respiratory Journal
researchProduct

Impact of hypertonic saline nebulisation combined with oscillatory positive expiratory pressure on sputum expectoration and related symptoms in cysti…

2018

Abstract Objective To evaluate the impact of combining nebulised hyaluronic acid plus hypertonic saline (HA + HS) with oscillatory positive expiratory pressure (oscillatory-PEP) on sputum expectoration and related symptoms in adults with cystic fibrosis (CF). Design Randomised crossover trial. Setting Seven centres. Participants Twenty-two outpatients with CF. Interventions Usual care (HA + HS followed by autogenic drainage) and combined therapy (HA + HS with oscillatory-PEP followed by autogenic drainage]. Each treatment was performed for 5 days. Main outcome measures Sputum expectoration was measured during the nebulisation period (primary outcome), during autogenic drainage and for 24 ho…

AdultMale030506 rehabilitationAdolescentCystic FibrosisPhysical Therapy Sports Therapy and RehabilitationCystic fibrosisPulmonary function testingPositive-Pressure RespirationYoung Adult03 medical and health sciences0302 clinical medicineAdministration InhalationmedicineHumansSingle-Blind Method030212 general & internal medicineHyaluronic AcidAdverse effectSaline Solution HypertonicCross-Over Studiesbusiness.industryNebulizers and VaporizersSputummedicine.diseaseCombined Modality TherapyCrossover studyConfidence intervalRespiratory Function TestsHypertonic salineClinical trialAnesthesiaSputumFemalemedicine.symptom0305 other medical sciencebusinessPhysiotherapy
researchProduct

The Effects of Isoflurane and Desflurane on Intracranial Pressure, Cerebral Perfusion Pressure, and Cerebral Arteriovenous Oxygen Content Difference …

2003

Background Desflurane is a volatile anesthetic agent with low solubility whose use in neurosurgery has been debated because of its effect on intracranial pressure and cerebral blood flow. The purpose of this study was to determine the variations on intracranial pressure (ICP) and cerebral perfusion pressure (CPP) as well as on cerebral arteriovenous oxygen content difference (AVDo(2)) in normocapnic patients scheduled to undergo removal of supratentorial brain tumors with no evidence of mass effect during anesthesia with isoflurane or desflurane. Methods In 60 patients scheduled to undergo craniotomy and removal of supratentorial brain tumors with no evidence of midline shift, anesthesia w…

AdultMaleAdolescentIntracranial PressureHemodynamicsBlood PressureDesfluraneHeart RateMonitoring IntraoperativemedicineHumansCerebral perfusion pressureAgedIntracranial pressureIsofluraneCerebrumbusiness.industryBrainSupratentorial NeoplasmsBlood flowMiddle AgedOxygenAnesthesiology and Pain Medicinemedicine.anatomical_structureIsofluraneCerebral blood flowCerebrovascular CirculationAnesthesiaAnesthetics InhalationFemalebusinessDesfluraneCraniotomymedicine.drugAnesthesiology
researchProduct

Effects of inhaled nitric oxide on primary graft dysfunction in lung transplantation.

2009

Introduction and Objectives. Inhaled nitric oxide (iNO) is a gaseous drug with known properties of specific pulmonary vasodilation and improved oxygenation. In some clinical trials on lung transplantation (LT) in animals, it has been demonstrated to reduce primary graft dysfunction (PGD) by limiting neutrophil adhesion and the inflammatory cascade. Our objective was to assess whether iNO showed this immunomodulatory effect by determining interleukin (IL)-6, -8, and -10 levels in blood and bronchoalveolar lavage (BAL) in LT patients, and its relationship with PGD incidence. Materials and Methods. Forty-nine LT patients were recruited and included in the iNO or in the control group. Patients …

AdultMaleAdolescentmedicine.medical_treatmentPrimary Graft DysfunctionNitric OxideNitric oxidechemistry.chemical_compoundYoung AdultPostoperative ComplicationsAdministration InhalationmedicineLung transplantationHumansRespiratory systemAgedTransplantationLungmedicine.diagnostic_testInhalationbusiness.industryInterleukin-6Interleukin-8respiratory systemMiddle AgedInterleukin-10TransplantationBronchoalveolar lavagemedicine.anatomical_structurechemistryAnesthesiaSurgeryFemalebusinessLung TransplantationTransplantation proceedings
researchProduct

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing

2004

Budesonide/formoterol in a single inhaler is an effective therapy for asthma. We investigated whether adjustable maintenance dosing with budesonide/formoterol could maintain health-related quality of life (HRQL) and asthma control.Asthma patients (n = 4025) received budesonide/formoterol (Symbicort 160/4.5 microg) 2 inhalations twice daily (b.i.d.) for 4 weeks during run-in of this open, multicentre study. Patients were randomised to adjustable dosing (budesonide/formoterol 1 inhalation b.i.d.; stepping up to 2 or 4 inhalations bid for 1 week if asthma worsened) or fixed dosing (budesonide/formoterol 2 inhalations b.i.d.), for 12 weeks. Change in HRQL (standardised Asthma Quality of Life Qu…

AdultMaleBudesonideAdolescentDrug Administration Scheduleimmune system diseasesFormoterol FumarateAdministration InhalationmedicineHumansAnti-Asthmatic AgentsMetered Dose InhalersDosingBudesonideAgedAsthmaInhalationbusiness.industryInhalerGeneral MedicineMiddle Agedmedicine.diseaseAsthmaRespiratory Function Testsrespiratory tract diseasesDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaQuality of LifeFemaleFormoterol FumarateFormoterolbusinessmedicine.drugCurrent Medical Research and Opinion
researchProduct

Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study

2012

SummaryBackgroundStudies with inhaled corticosteroids (ICS) in smoking asthmatics have mostly shown poorer treatment responses than in non-smoking asthmatics.MethodsEuroSMART, an open, randomised, 6-month study, compared budesonide/formoterol (Symbicort ® Turbuhaler®)hhNeither the Symbicort SMART posology nor the dry powder formulation, Turbuhaler, is currently approved in the US. maintenance and reliever therapy (Symbicort SMART®) at two maintenance doses of budesonide/formoterol (160/4.5 μg), 1 × 2 and 2 × 2, in patients with asthma who were symptomatic despite treatment with ICS ± long-acting β2-agonists. The 8424 randomised patients included 886 smokers (11%; aged <40 years or with a sm…

AdultMaleBudesonidePulmonary and Respiratory MedicineSymbicort SMARTmedicine.medical_specialtyPeak Expiratory Flow RatePropensity-matched controlsDrug Administration Schedulelaw.inventionACQ-5Budesonide/formoterol maintenance and reliever therapyPharmacotherapyRandomized controlled triallawFormoterol FumarateSurveys and QuestionnairesInternal medicineAdministration InhalationmedicineHumansAnti-Asthmatic AgentsDosingBudesonideAsthmaSmokersDose-Response Relationship Drugbusiness.industrySmokingmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionDrug Therapy CombinationFemaleFormoterol FumarateFormoterolbusinessmedicine.drugRespiratory Medicine
researchProduct